Supreme Court Awards Rs. 6 Lakh to Man Acquitted After 6 Years, Faults UP Police Probe || Supreme Court: High Courts Can Restore Power on 50% Deposit in Arbitrary Theft Assessments || Supreme Court: Cooperative Society Cannot Deny RTI Records as Personal if Registrar Can Access Them || SC: CoC Cannot Withdraw Approved Resolution Plan Over Improved Corporate Debtor Finances || Delhi High Court: 24-Week Limit Alone Cannot Restrict Medical Termination of Pregnancy || Allahabad High Court Rejects Challenge to 18% GST on Online Legal Database Services || Madras High Court: FIR Registration Does Not Decide Guilt; Prior Hearing of Accused Not Required || Kerala High Court Orders Speedy Prosecution Sanction Process in Sabarimala Gold Theft Case || Allahabad HC: Missing RT-PCR Report Cannot Bar COVID-19 Compensation if Records Confirm Infection || MP High Court Directs Indore Police to Deploy Volunteers for Reporting Noise Pollution Violations

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :